TPST
Tempest Therapeutics, Inc.
Next earnings Aug 10, 2026 (after close) · consensus $-0.31 EPS
$1.08
▲ +2.86%$1.08▼ -84.07%
over 1Y
L $1.05EODHDH $11.83
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.9%
1W-13.6%
1M-39.7%
3M-37.6%
YTD-63.4%
1Y-84.1%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Revenue fell -54.8% YoY.
Tempest Therapeutics, Inc. shows $295K in FY2017 revenue (-54.8% YoY), a -8902.4% net margin, and -393.9% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$27.0M | -$34.6M | -$29.2M | -$42.0M | -$26.6M |
| Net income | -$28.3M | -$35.7M | -$29.5M | -$41.8M | -$26.3M |
| Diluted EPS | -$7.47 | -$3.09 | -$1.91 | -$19.50 | -$6.33 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$7.78M
EV / EBITDA—
EV / Sales26.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-169.5%
FCF yield-173.1%
Quality & risk
ROIC (est.)-314.9%
Free cash flow-$26.8M
Total debt$0.00
Net cash$7.71M
Altman Z-Score-23.20 distress
Piotroski F-Score4/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-68.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — delisting notice (2026-05-22). Worth a closer look.
- S-3 Shelf registration (potential raise)2026-06-26
- 8-K Shareholder vote2026-06-23
- DEF 14A Proxy statement2026-06-08
- 8-K Officer / director change2026-06-04
- 8-K Material agreement2026-06-02
- 8-K Officer / director change2026-05-29
- 8-K Delisting notice2026-05-22
- 8-K Officer / director change2026-05-22
- 10-Q Quarterly report2026-05-14
Recent filings
all on EDGAR ↗S-3Filing2026-06-26open ↗4Period ending 2026-03-242026-06-23open ↗8-KPeriod ending 2026-06-182026-06-23open ↗DFiling2026-06-23open ↗4Period ending 2026-06-042026-06-17open ↗3Period ending 2026-06-042026-06-17open ↗3Period ending 2026-06-042026-06-08open ↗4Period ending 2026-06-042026-06-08open ↗DEF 14APeriod ending 2026-06-182026-06-08open ↗8-KPeriod ending 2026-05-292026-06-04open ↗8-KPeriod ending 2026-05-282026-06-02open ↗PRE 14APeriod ending 2026-06-182026-05-29open ↗
Frequently asked
- Is Tempest Therapeutics, Inc. (TPST) a buy?
- TPST currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Revenue fell -54.8% YoY.
- What is Tempest Therapeutics, Inc.'s quality score?
- TPST scores 37.15686274509804/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001544227, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 7:14:47 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.